Telo Genomics Corp (TSE:TELO) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and low-risk smoldering myeloma patients. This innovative test could transform patient management by offering a non-invasive method to monitor disease progression, addressing a significant market opportunity.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
